2133P - Sleep disorders: Evolution in time in early breast cancer (EBC)

Background

Sleep disorders are common in the general population and among all cancer patients, but it has been shown that they are particularly prevalent among patients diagnosed with breast cancer, both during and after treatment. These disruptions produce a significant deterioration in functional status and clearly reduce the quality of life of the patients.

Methods

126 women diagnosed with EBC at Puerta de Hierro Hospital have been analyzed, divided into 3 groups. The first group were women with a recently breast cancer diagnosis reciving chemotherapy, the second group were women at early follow up (first two years post-diagnosis), and the third group were women at late follow up (more than 2 years after diagnosis). The control group was selected from a sample of healthy individuals matched with our patients in terms of age, weight, and physical condition (digital twin). Sleep parameters were obtained using a wearable device for 7 consecutive days (Kronowise®-Kronohealth S.L).

Results

The patients undergoing active chemotherapy treatment exhibited more disrupted sleep patterns than controls, with a delay in their circadian rhythms and more aged rhythms. 25% of them slept less than 6 hours, and the average nocturnal sleep duration in this population was 6.73 hours. They frequently resorted to napping, with 55% of them taking naps longer than 30 minutes, with a sleep efficiency of less than 80%. As time passed from the diagnosis, the sleep patterns began to resemble those of the control group, and no differences with controls were found in the third group of patients. The sleep efficiency improved in the late follow-up group, with an efficiency rate exceeding 85%.

Conclusions

The administration of chemotherapy in patients with early breast cancer produces significant disruptions in sleep, with a clear impact on their quality of life, which can be recovered with long-term follow-up (more than 2 years since diagnosis). We must make an effort to detect these problems and instruct our patients in healthy sleep habits.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This abstract is part of the CLARIFY project that has received funding from the European Union’s Horizon 2020 Research and Innovation Programme under grant agreement No. 875160.

Disclosure

All authors have declared no conflicts of interest.